TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
A legfontosabb adatok
- Ki végzi
- Reva Basho
- Hol
- Los Angeles (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Visszavonva
- Fázis
- 1/2. fázis
- Kezdés
- 2022. jún. 1.
- Befejezés
- 2024. jún. 1.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Tucatinib
- Pembrolizumab
- Trastuzumab
- A regiszteradat frissítve
- 2022. július 1.
- Miért állt le
- Study withdrawn due to change in treatment landscape for HER2+ metastatic breast cancer.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥18 years
- ECOG performance status of 0-2
- HER2+ (as defined by ASCO/CAP clinical practice guideline) metastatic breast cancer
- Untreated or previously treated and progressing CNS disease
- Measurable CNS metastases
- Must be able to undergo MRI of the brain
- Adequate organ function
Ki nem vehet részt
- Any indication for immediate CNS-directed therapy
- Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor
- Prior therapy with tucatinib
- History of generalized or complex partial seizures
- Leptomeningeal disease
- Active autoimmune disease that has required systemic treatment in excess of prednisone 10mg daily or equivalent in the past 2 years; Complete inclusion/exclusion criteria are detailed in the protocol
- Any other manifestation of neurologic progression that in the opinion of the treating physician is due to brain metastases
Helyszínek itt: Egyesült Államok
- Cedars-Sinai Medical CenterLos Angeles, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a single arm, open label trial to assess the safety and efficacy of tucatinib in combination with pembrolizumab and trastuzumab for the treatment of HER2+ breast cancer brain metastases (BCBM). A total of 33 patients with untreated or previously treated and progressing HER2+ BCBM not requiring urgent central nervous system (CNS)-directed therapy will be enrolled. The study will determine the recommended dose of tucatinib in this combination and assess the efficacy of this combination in controlling CNS disease in patients with HER2+ BCBM.
A vizsgálat csoportja
- Tucatinib + Pembrolizumab + TrastuzumabA vizsgált kezelés
Patients will receive a combination therapy of tucatinib with pembrolizumab and trastuzumab during the treatment period until progression, treatment intolerance, or patient withdrawal from study. Tucatinib and pembrolizumab are administered as experimental use while trastuzumab is administered per standard use. Patients are expected to be on treatment for at least 12 weeks.
Kezelés: Tucatinib, Pembrolizumab és Trastuzumab
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- TOPAZ: Single Arm, Open Label Phase 1b/2 Study of Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
- A regiszteradat frissítve
- 2022. július 1.